POSEIDA THERAPEUTICS INC (PSTX)
US73730P1084 - Common Stock
Overall PSTX gets a fundamental rating of 2 out of 10. We evaluated PSTX against 564 industry peers in the Biotechnology industry. Both the profitability and financial health of PSTX have multiple concerns. PSTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PSTX had negative earnings in the past year.
In the past year PSTX has reported a negative cash flow from operations.
In the past 5 years PSTX always reported negative net income.
PSTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PSTX (-20.70%) is better than 76.84% of its industry peers.
PSTX has a Return On Equity (-69.67%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| ROIC | N/A |
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PSTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PSTX has more shares outstanding
PSTX has a worse debt/assets ratio than last year.
2.2 Solvency
PSTX has an Altman-Z score of 0.23. This is a bad value and indicates that PSTX is not financially healthy and even has some risk of bankruptcy.
PSTX has a better Altman-Z score (0.23) than 64.45% of its industry peers.
PSTX has a Debt/Equity ratio of 0.68. This is a neutral value indicating PSTX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.68, PSTX is doing worse than 76.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.23 |
ROIC/WACCN/A
WACC10.87%
2.3 Liquidity
A Current Ratio of 3.20 indicates that PSTX has no problem at all paying its short term obligations.
PSTX's Current ratio of 3.20 is on the low side compared to the rest of the industry. PSTX is outperformed by 61.94% of its industry peers.
A Quick Ratio of 3.20 indicates that PSTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.20, PSTX is doing worse than 60.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.28% over the past year.
Looking at the last year, PSTX shows a very strong growth in Revenue. The Revenue has grown by 202.93%.
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%
3.2 Future
Based on estimates for the next years, PSTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.75% on average per year.
The Revenue is expected to grow by 52.27% on average over the next years. This is a very strong growth
EPS Next Y30.29%
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
EPS Next 5Y16.75%
Revenue Next Year217.39%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y52.27%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
PSTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
5. Dividend
5.1 Amount
No dividends for PSTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
POSEIDA THERAPEUTICS INC
NASDAQ:PSTX (1/2/2025, 5:18:36 PM)
After market: 9.4101 +0.01 (+0.11%)9.4
-0.2 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.52%
Inst Owner Change0.95%
Ins Owners0.89%
Ins Owner Change0%
Market Cap916.22M
Analysts74.55
Price Target9.18 (-2.34%)
Short Float %5.1%
Short Ratio2.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.77%
Min EPS beat(2)23.01%
Max EPS beat(2)150.52%
EPS beat(4)4
Avg EPS beat(4)61.65%
Min EPS beat(4)23.01%
Max EPS beat(4)150.52%
EPS beat(8)6
Avg EPS beat(8)25.24%
EPS beat(12)9
Avg EPS beat(12)43.35%
EPS beat(16)12
Avg EPS beat(16)33.55%
Revenue beat(2)2
Avg Revenue beat(2)198.71%
Min Revenue beat(2)64.99%
Max Revenue beat(2)332.43%
Revenue beat(4)4
Avg Revenue beat(4)200.6%
Min Revenue beat(4)64.99%
Max Revenue beat(4)332.43%
Revenue beat(8)6
Avg Revenue beat(8)122.25%
Revenue beat(12)10
Avg Revenue beat(12)1069.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-35.71%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.28%
EPS NY rev (1m)-34.28%
EPS NY rev (3m)32.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)69.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.51 | ||
| P/tB | 11.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.63
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.55
BVpS0.89
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.31% | ||
| Cap/Sales | 1.39% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.2 | ||
| Altman-Z | 0.23 |
F-Score4
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)62.75%
Cap/Depr(5y)254.95%
Cap/Sales(3y)5.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y30.29%
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
EPS Next 5Y16.75%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%
Revenue Next Year217.39%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y52.27%
EBIT growth 1Y54.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.41%
OCF growth 3YN/A
OCF growth 5YN/A